Pharmaceuticals

Daiichi Sankyo and Merck Initiate Phase 3 Study to Evaluate Safety and Efficacy of Ifinatamab Deruxtecan in Patients with Recurrent Small Cell Lung Cancer

bexib
By bexib 0 Min Read

IDeate-Lung02 will compare ifinatamab deruxtecan to physician’s choice of chemotherapy in patients with recurrent small cell lung cancer.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Occupy Bitcoin: Bitcoin is not just libertarian
Next Article Asia FX firms bet on rate cut, yen hits 5-month high on hawkish BoJ stance Investing.com – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Christmas has arrived at Orelle – Luxury Hospitality Magazine
Hospitality & Tourism
A look inside: Allies developing a multicloud hybrid strategy
Banking
2024 Holiday Shipping Deadline for the United States
International Shipping
Ecommerce taxes – How to stay ahead of the sales tax maze
Retail & E-commerce